Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 15/20 | 0.63 |
| ▸ | TUBB | P07437 | 15/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 15/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 15/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 15/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 15/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 15/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 15/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 15/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 15/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 15/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 15/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 15/20 | 0.63 |
| ▸ | TUBB2B | Q9BVA1 | 15/20 | 0.63 |
| ▸ | TUBB1 | Q9H4B7 | 15/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | FLT4 | P35916 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabizabulin SCHEMBL724794 | 1.00 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL26612334 | 0.99 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL26612407 | 0.96 | TUBB4A (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL26612327 | 0.95 | TUBB4A (0.58) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL29728525 | 0.95 | TUBB4A (0.58) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL29728516 | 0.94 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL29728501 | 0.94 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Sabizabulin SCHEMBL29728500 | 0.93 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL786594 | 0.91 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10283196 | 0.91 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | claimed |
| US-20250295633-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| EP-4601645-A1 | THERAPEUTIC COMBINATIONS AND METHODS TO TREAT LONG COVID | Dixit, Rohan (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250236660-A1 | THERAPEUTIC COMBINATIONS AND METHODS TO TREAT LONG COVID | DIXIT ROHAN (US) | 2025-07-24 | — | — | US | claimed |
| US-20250213469-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. | 2025-07-03 | — | — | US | claimed |
| WO-2025125788-A1 | SABIZABULIN FOR USE IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | HEALX LTD (GB) | 2025-06-19 | — | — | WO | claimed |
| EP-4514342-A1 | POLYMORPHS OF [2-(1-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5- TRIMETHOXY)METHANONE AND ITS SALTS | Veru Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4493276-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. (TR) | 2025-01-22 | — | — | EP | claimed |
| CN-119212696-A | Polymorphs of [2- (1H-indol-3-yl) -1H-imidazol-4-yl ] (3, 4, 5-trimethoxy) methanone and salts thereof | 维鲁公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2023177367-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. (TR) | 2023-09-21 | — | — | WO | claimed |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| WO-2023101710-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | VERU INC. (US) | 2023-06-08 | — | — | WO | claimed |
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | VERU, INC. (US) | 2023-06-08 | — | — | US | claimed |
| CN-115803023-A | Method of treating patients infected with coronavirus with nerzetinib | 施万生物制药研发IP有限责任公司 | 2023-03-14 | — | — | CN | claimed |
| US-20230021647-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC | 2023-01-26 | — | — | US | claimed |
| WO-2022271604-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | claimed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | claimed |
| US-20220257552-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | VERU, INC. (US) | 2022-08-18 | — | — | US | claimed |
| WO-2022174121-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | VERU, INC. (US) | 2022-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | AR, CYP19A1, NR5A1 | TUBB4A 2819/4885TUBB 3325/4885TUBA3C 3037/4885 |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | SHBG, AR, HSD17B11 | TUBB4A 1311/4885TUBB 958/4885TUBA3C 2024/4885 |
| US-20220257552-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | PGR, TTK, CDK6 | TUBB4A 1488/4885TUBB 1431/4885TUBA3C 2227/4885 |
| US-20230021647-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | ALB, ACE, ACE2 | TUBB4A 2965/4885TUBB 2945/4885TUBA3C 2787/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | TUBB4A 3826/4885TUBB 4323/4885TUBA3C 3350/4885 |
| US-20250295633-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | SHBG, AR, HSD17B11 | TUBB4A 1311/4885TUBB 958/4885TUBA3C 2024/4885 |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | SERPINB1, ELANE, MPO | TUBB4A 1110/4885TUBB 1192/4885TUBA3C 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.